Labetalol in the Treatment of Essential Hypertension: A Single‐Blind Dose Ranging Study

Shlomo Dux, Itamar Grosskopf, Geoffrey Boner, Joseph B. Rosenfeld

Research output: Contribution to journalArticlepeer-review


The hypotensive efficacy of labetalol was evaluated in 29 patients with essential hypertension in a single‐blind dose ranging study. After a two‐week period of placebo treatment, labetalol was given in oral doses of 0.6 g/d, 0.8 g/d, and 0.8 g/d combined with 25–50 mg/d of hydrochlorothiazide. Each regimen lasted four weeks. The decrease in blood pressure was dose dependent: 90% of patients showed a significant reduction in diastolic blood pressure and 75% showed a significant reduction in systolic blood pressure. In 69% of the patients, side effects of the drug were noted, and in five patients (17%), treatment was discontinued because of the side effects. Seven patients received labetalol intravenously before the oral treatment. Their heart rate and blood pressure reductions were similar to those found in patients only taking the medication orally. We conclude that labetalol is an efficient and safe antihypertensive agent in both oral and intravenous administration. However, the high incidence of side effects makes labetalol a drug of second choice in uncomplicated hypertensive patients. 1986 American College of Clinical Pharmacology

Original languageEnglish
Pages (from-to)346-350
Number of pages5
JournalJournal of Clinical Pharmacology
Issue number5
StatePublished - 1986


Dive into the research topics of 'Labetalol in the Treatment of Essential Hypertension: A Single‐Blind Dose Ranging Study'. Together they form a unique fingerprint.

Cite this